



PRESS RELEASE FOR IMMEDIATE USE

Dechra Veterinary Products Announces Availability of VETORYL[®] Capsules (trilostane) in new 5mg Strength

Dechra Veterinary Products is proud to announce that FDA's Center for Veterinary Medicine approved an additional strength of VETORYL[®] Capsules (trilostane). 5mg VETORYL Capsules will be available for purchase through authorized veterinary distributors in mid to late September.

This new 5mg strength will help veterinarians treat their smaller patients and will alleviate the need to have smaller doses of trilostane compounded. A study published in the Journal of the American Animal Hospital Association in the July/August 2012 edition by Dr Audrey Cook from Texas A&M concluded the following about compounded trilostane, "Trilostane content of compounded capsules may vary from the prescribed strength, and dissolution characteristics may not match those of the licensed product. The use of compounded trilostane products may therefore negatively impact the management of dogs with hyperadrenocorticism." VETORYL Capsules are the proven, safe, and effective, FDA-approved option for trilostane. 5mg VETORYL Capsules will provide veterinarians with a high-quality option for their small patients that they can trust.

VETORYL Capsules (trilostane) are now available in five strengths: 5mg, 10mg, 30mg, 60mg and 120mg. When appropriate, 5mg VETORYL Capsules can also be used in combination with other available strengths to achieve a more precise dosing for patients. For technical support on VETORYL Capsules please contact Dechra's Veterinary Technical Support at (866) 933-2472. For further information, including the full prescribing information, and educational and client resources, please visit www.dechra-us.com.



Dechra Veterinary Products, located in Overland Park, Kansas is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra Veterinary Products' companion animal portfolio includes VETORYL[®] Capsules (trilostane), FELIMAZOLE[®] (methimazole) Coated Tablets, ANIMAX[®] OINTMENT (nystatin, neomycin sulfate, thiostrepton, triamcinolone acetonide ointment), VETROPOLYCIN[®] (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment and VETROPOLYCIN[®] HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment, PHYCOX[®] joint health supplements, MURICIN[®] (mupirocin ointment 2%), as well as an extensive topical dermatologic line for veterinary use. Dechra's equine portfolio includes OSPHOS[®] (clodronate injection), Orthokine[®] vet irap 10 and 60, Osteokine[®] (PRP), and EQUIDONE[®] (domperidone) Gel. For more information, please visit www.dechra-us.com or call (866) 933-2472.

Contact:

Dr Nancy Zimmerman

Director of US Marketing

Dechra Veterinary Products

Nancy.zimmerman@dechra.com